MAGNUS JAKOBSSON is Associate Senior Lecturer in Proteomics at the Department of Immunotechnology, Medicon Village, Lund University, and part of the Lund University Cancer Center (LUCC).
WHAT IS THE FOCUS OF YOUR RESEARCH?
My research focuses on how proteins are regulated by so-called Post Translational Modifications (PTMs) in health and disease. For this, we use high-end mass spectrometry which allows us to identify and quantify thousands of cellular proteins, and their PTMs, in a single analysis.
WHAT IMPACT DO YOU HOPE THAT YOUR RESEARCH WILL HAVE ON CANCER CARE/CANCER PATIENTS?
Hereditary and obtained defects in our genes give rise to dysfunctional proteins. In particular, enzymes that introduce PTMs are frequently dysregulated in disease states such as cancer. A better understanding of PTM biology is thus anticipated to uncover both new biomarkers and therapeutic targets. In turn, this will directly benefit cancer patients through improved diagnostics and therapy.
WHAT ARE THE POSSIBILITIES FOR COMMERCIALIZING YOUR RESEARCH?
The PTM status of proteins typically reflect their activity and is overlooked in the bulk of today’s protein-based diagnostic tests. The novel PTM-specific affinity agents generated as part of our research efforts may provide additional layers of information, reflecting protein function, in next generation diagnostics.
WHERE CAN I READ MORE ABOUT YOU AND YOUR RESEARCH?